Telix Pharmaceuticals Ltd
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Large accelerated filer
State of Incorporation
Australia
Business Address
55 FLEMINGTON ROAD, NORTH MELBOURNE, C3, 3051
Mailing Address
55 FLEMINGTON ROAD, NORTH MELBOURNE, C3, 3051
Phone
61 3 9093 3855
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | April 7, 2026 | View on SEC |
| 6-K Foreign company current report | April 2, 2026 | View on SEC |
| 3 Initial insider ownership report | April 1, 2026 | View on SEC |
| 3 Initial insider ownership report | April 1, 2026 | View on SEC |
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| 3 Initial insider ownership report | April 1, 2026 | View on SEC |
| 3 Initial insider ownership report | April 1, 2026 | View on SEC |
| 20-F/A Foreign annual report amendment | March 20, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
Annual Reports
20-F
February 20, 2026
- Achieved significant revenue growth, primarily from Illuccix, and moved into net profitability in 2023.
- Maintained a strong cash position, providing ample liquidity for ongoing operations and pipeline development.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.